Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".
Press Release Dec 19 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The agreement includes the introduction of several tests aimed at improving cancer care and personalized treatment options for patients. This collaboration is expected to enhance access to precision oncology and support clinicians in making informed treatment decisions. The press release outlines the significance of these tests in identifying hereditary cancer risks and aiding in disease management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 15 2025
- Press Release Dec 10 2025
- Press Release Dec 09 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 04 2025
Later from Zydus Lifesciences
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 23 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
- Zydus Lifesciences Limited Press Release Jan 13 2026
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences